A 23-year-old woman with juvenile-onset a-mannosidosis developed an axonal polyneuropathy more than a year following successful unrelated donor (URD) BMT complicated by chronic graft-versus-host disease (GVHD). Progressive muscle weakness and paresthesias developed over at least 4 months, and made her nonambulatory. Nerve conduction and EMG studies demonstrated an axonal sensorimotor neuropathy. Cerebral spinal fluid (CSF) IgG was elevated with two peaks not identified in serum. Strength improved after a single course of plasma exchange and continued to improve over 12 months. The response to plasma exchange, elevated CSF IgG production, and evidence of a serum IgM peak suggest an immune-mediated mechanism. Chronic polyneuropathies following BMT are rare and are usually temporally related to GVHD or infection. This patient's disease was unusual because of its late occurrence and chronic onset in the face of resolved GVHD and in the absence of infection. Bone Marrow Transplantation (2003) 32, 953-955.
axonal neuropathy
Alpha-mannosidosis is a rare, autosomal recessive lysosomal storage disease characterized by mental retardation, hepatosplenomegaly, dysostosis multiplex, and death in childhood. A milder, juvenile-onset form, present in 10-15% of cases, has a later onset and slower progression. Survival into young adulthood is possible for patients with this form. 1 Peripheral neuropathy has been associated with b-mannosidosis, a related storage disorder, but is not known to occur in a-mannosidosis. 1 No specific treatment for a-mannosidosis is available, although improvement after BMT has been reported in a small number of cases. 2 Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) has been described following BMT as well as solid organ transplantation. [3] [4] [5] [6] Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been reported in association with graft-versus-host disease (GVHD) or infection. 7, 8 An acute motor axonal neuropathy (AMAN) has been associated with Campylobacter jejuni and other infections, [9] [10] [11] but no chronic form has been described. We report a case of a chronic sensorimotor axonal, polyradiculoneuropathy complicating BMT for a-mannosidosis.
Case report
A 23-year-old woman diagnosed with juvenile-onset a-mannosidosis underwent an unrelated donor (URD) BMT in June 1999. A diagnosis of a-mannosidosis was made following spondylolysthesis repair at age 18. In retrospect, the disease manifested earlier with slowly decreasing cognition, dysarthria, ataxia, and facial coarseness. She underwent an unrelated BMT in June 1999 with a T-cell-depleted marrow after a preparative regimen including cyclophosphamide, busulfan, and TBI complicated by radiation nephritis and CMV retinitis requiring foscarnet therapy for control.
The patient developed histologically confirmed cGVHD of the skin 6 months following transplant. This was associated with an oligoclonal IgM gammopathy of 2300 mg/dl (normal 60-265 mg/dl). The rash responded promptly to immunosuppressive therapy with cyclosporine (CSA) and prednisone. At 11 months post transplant, she developed a change in cognitive function marked by hyperphagia, loss of communication, and combativeness with abnormal signal intensity in the brainstem and thalamus by MRI. Cerebral spinal fluid (CSF) examination was normal. These clinical symptoms spontaneously resolved over the next 3 months, and the etiology of this decline remains unknown. MRI appearances returned to normal. CSA was successfully discontinued and steroid therapy was tapered off by 18 months post BMT.
Approximately 19 months following transplant, the patient experienced slowly progressive muscle weakness and painful paresthesias that progressed over a 6-8 week period. She had discontinued all immune suppression, her cGVHD had resolved, and she had no evidence of active infection. Neurologic examination showed mild generalized weakness with ability to stand on toes but not heels, a wide based gait, and upper extremity dysmetria. She was areflexic. A brain MRI was normal.
Electrophysiologic studies performed 12 weeks after the onset of weakness showed widespread fibrillation potentials with small motor units, low amplitude compound muscle action potentials, absent F waves, and an absent sural response.
Examination 16 weeks into the illness demonstrated distal upper extremity wasting, diffusely decreased tone in the trunk and extremities, and both proximal and distal weakness in the upper and lower extremities. She continued to have absent reflexes, a mild vibration sense deficit at the great toes, and was unable to stand or walk independently.
CSF protein was 93 mg/dl (nl 15-60 mg/dl) with normal glucose and cell count. CSF IgG was elevated at 6.8 mg/dl (nl o6.0 mg/dl), as was the IgG/albumin ratio of 0.36 (nl 0.09-0.25). Two oligoclonal bands not detected in serum were present in the CSF. A PCR test for CMV on the CSF was negative. The serum IgM level was significantly lower than when the patient had active cGVHD but was still elevated at 413 mg/dl (60-265 mg/dl). Assays for HHV-6, JC virus, and BK virus were not performed since these are typically not associated with autoimmune neuropathies.
The patient was treated with five double volume plasma exchanges over the course of 10 days. Clinical improvement in strength was evident after completion of the third treatment and her strength continued to improve gradually thereafter. At 8 months following plasma exchange, the patient had normal strength in the upper extremities, mild residual weakness in the lower extremities, and was able to walk with minimal assistance. By 12 months after her treatment, she had return of patellar reflexes and improved muscle bulk in her intrinsic hand muscles and could walk unaided.
Discussion
Our patient developed a gradually progressive areflexic quadriparesis, paresthesias, sensory loss, electrodiagnostic evidence of polyneuropathy, and elevation of the CSF protein. Her strength improved promptly after initiation of plasma exchange. These features are consistent with an immune-mediated polyneuropathy.
The commonly recognized categories of immunemediated polyneuropathy include AIDP (or Guillain-BarreŚ yndrome), CIDP, peripheral nerve vasculitis, and AMAN. Our patient had a monophasic illness with electrophysiological features of an axonopathy rather than a demyelinating process, consistent with AMAN. Unlike patients with AMAN, however, the condition progressed gradually over a period of several months. Peripheral nerve vasculitis can present with this time course, but usually with a multi-focal distribution. Neuropathy is a rare complication of BMT. AIDP is the most common, although CIDP has been reported as well. 7, 8 While some cases of drug-induced axonal neuropathies have been reported, 12 to our knowledge no cases of AMAN have been described following BMT. This axonal process was first reported in 1993, affecting children in rural China; 9 however, sporadic cases have subsequently been published. 10 All cases have presented with an acute symmetric paralysis with predominately motor involvement. Patients are usually areflexic. Electrophysiologic studies are significant for findings of axonal degeneration rather than demyelination.
Most cases of immune-mediated polyneuropathy in BMT patients have been temporally related to either GVHD or infection. 13, 14 While our patient's course was complicated by cGVHD and CMV infection, treatment for these was nearly completed when the symptoms began. A steroid wean had just finished as her weakness became evident. CSA therapy had been discontinued a year prior to this illness and there was no evidence of active GVHD. CMV antigenemia tests were negative and subsequent ophthalmologic exams all revealed quiescent retinitis. It is therefore unlikely that the neuropathy was related to cGVHD or CMV infection.
Although our patient's polyneuropathy did not occur at the time of active cGVHD, the presence of an elevated CSF protein, oligoclonal bands in the CSF, and an apparent response to plasma exchange all suggest that the disease was immune-mediated. AIDP and CIDP are known to be associated with endoneurial infiltration of T lymphocytes and subsequent macrophage-mediated demyelination. While T-cell immune studies were not performed, our patient was a young adult who received a T-depleted graft, and immunosuppressive therapy for cGVHD. It is likely that she did not yet have full T-lymphocyte reconstitution and had some level of impaired cell-mediated immunity. We can only speculate that her condition may have been antibody-mediated.
An episode of severe neurologic deterioration did occur approximately 11 months after transplant. This was preceded by hyperphagia and marked by decreased cognition and increased combativeness. Hyperphagia has been described in a-mannosidosis 15 and all these symptoms spontaneously resolved over a period of 6-12 months. It is possible that this decline was related to the underlying storage disease since it occurred prior to the time that increased a-mannosidase enzyme level in the CNS might be expected to change the natural history of the disease. These events are unlikely to have been related to the chronic progressive neuropathy.
In summary, this case illustrates the importance of a thorough investigation of neurological symptoms following BMT, even in those patients with established neurologic diseases. These events may be immune-mediated and amenable to therapy.
